The deal between Allergan PLC and Forest Laboratories Inc., which is likely to close mid-year, is indicative of many trends in biopharma, but one stands out: generics companies and branded specialty pharmas, long considered difficult to run under one roof, are converging into hybrid models.
While companies have sought for years to combine generics and branded innovative businesses, they have had mixed success at best;...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?